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Placebo response in trichotillomania
Jon E. Granta, Samuel R. Chamberlainf,g, Sarah A. Reddena, Brian L. Odlaugd,e,
Michael van Ameringenh, Darin D. Doughertyb, Nancy J. Keuthenb and
Suck W. Kimc
Trichotillomania is a functionally impairing, often overlooked
disorder with no Food and Drug Administration-approved
medications indicated for its treatment. The ability of clinical
trials to detect the beneficial effects of pharmacologic
treatment in trichotillomania has been hampered by the
high placebo response rate. Very little is known about
baseline demographic and clinical characteristics that may
be predictive of placebo response in such patients. Overall,
104 participants assigned to placebo were pooled from five
double-blind trials conducted at three sites in the USA and
Canada. Participants were classified as placebo responders
or nonresponders on the basis of a cutoff of a 35%
reduction in symptom severity on the Massachusetts
General Hospital Hair Pulling Scale. Baseline group
differences were characterized using t-tests and equivalent
nonparametric tests as appropriate. Thirty-one percent of
individuals assigned to placebo treatment showed a
significant clinical response to placebo. Placebo responders
(n= 32) and nonresponders (n= 72) did not differ
significantly on any demographic or clinical variable.
Predictors of placebo response for trichotillomania
remain elusive and do not appear to be similar to those
reported for other mental health disorders. Int Clin
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Introduction
Trichotillomania (TTM) is a potentially disabling, under-
recognized condition in which individuals repeatedly pull
out their hair, leading to hair loss. Psychosocial problems
are common among individuals with TTM and may
include significantly reduced quality of life, lowered self-
esteem, and impaired social functioning (Diefenbach
et al., 2005; Houghton et al., 2016; Grant and Chamberlain,
2016). Although TTM has been described for almost two
centuries, it remains poorly understood, with limited data
on pathophysiology and treatment (Christenson and
Mansueto, 1999; Chamberlain et al., 2009; Grant and
Chamberlain, 2016).
Most of the double-blind, placebo-controlled pharmacolo-
gical studies of TTM have failed to separate symptomatic
changes significantly from placebo. Interestingly, our clin-
ical experience suggests that in many cases, this lack of
effectiveness seems less to do with the medication failing
to produce results and more to do with the high placebo
response rates. For example, in a double-blind study of
inositol, 37% of the placebo group (using a last observation
carried forward approach) responded (Leppink et al., 2017).
Understanding the complexity of the placebo response in
these disorders is challenging because of the limited sizes
of the research samples (e.g. sample sizes of <25 taking
placebo in any single study). The present study seeks to
overcome this limitation by using a relatively large dataset
that combines participants from five double-blind, placebo-
controlled pharmacological trials in TTM conducted in the
USA and Canada (Dougherty et al., 2006; Grant et al., 2009,
2014; Van Ameringen et al., 2010; Leppink et al., 2017).
Understanding the factors associated with a placebo
response in TTM may allow for a more efficient exam-
ination of potentially beneficial pharmacological treat-
ments for this disabling disorder. Here, we pooled data
from studies in which all participants fulfilled the diag-
nostic criteria for TTM, took placebo pills, and were seen
regularly by a medical professional. Many factors have
been suggested to contribute toward the high placebo
response rates of clinical trials in mental health. In the case
of major depressive disorder, interpersonal interactions,
the strength of the therapeutic alliance with research
personnel (Leuchter et al., 2014), or lower levels of
depression severity (Khan et al., 2002, 2005) may result in a
placebo response. Data from trials of bipolar depression
suggest that baseline illness severity and trial duration
predict placebo response (Nierenberg et al., 2015). The
case of obsessive-compulsive disorder (OCD), however,
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has yielded no clear clinical variables associated with the
placebo response (Mataix-Cols, et al., 1999). On the basis
of the (admittedly limited) extant mental health literature
and our clinical experience, we hypothesized that the
placebo effect in TTM would be associated with milder
illness severity at baseline.
Participants and methods
Participants
Data from participants in TTM treatment studies at the
University of Chicago, University of Minnesota,
McMaster University, and Massachusetts General
Hospital (MGH)/Harvard Medical School who were
assigned to placebo during the clinical trial were included
in this study (one exception was the sertraline trial, which
had a 2-week single-blind placebo phase before treat-
ment assignment in the double-blind portion of the study
and only two were randomized to placebo treatment in
this study arm). All participants had a primary diagnosis of
TTM on the basis of expert clinical assessment. As is
customary in TTM research, before May 2013, the
diagnosis was made on the basis of Diagnostic and
Statistical Manual of Mental Disorders, 4th ed. (DSM-IV)
criteria with or without the endorsement of increasing
and decreasing tension associated with pulling (criteria B
and C). After the release of the DSM-V in May 2013, all
patients fulfilled the DSM-V criteria for TTM. Other
inclusion criteria included age 18 years or older, the
ability to be interviewed in person, and able to provide
written informed consent. Participants from MGH were
excluded if they fulfilled the criteria for a lifetime diag-
nosis of psychosis, autism, or mental retardation.
Participants at the University of Chicago and the
University of Minnesota were excluded if they were
pregnant, fulfilled the lifetime criteria for bipolar disorder
or a psychotic disorder, or had an organic mental disorder.
Participants taking any psychotropic medications were
included as long as the dose of medication had been
stable for at least 3 months before study entry.
Participants taking part at McMaster University were
excluded if they had comorbid primary mental disorders;
were less than moderately ill at baseline; had received
olanzapine without success in the past; had comorbid
OCD, depression, substance use disorder; or had a life-
time history of schizophrenia, bipolar disorder, dementia,
or other neurologic disorders.
All study procedures were carried out in accordance with
the latest version of the Declaration of Helsinki. Study
approvals were received from the Institutional Review
Boards of all relevant institutions before study initiation.
Detailed methodologies of the various clinical trials have
been published previously (Dougherty et al., 2006; Grant
et al., 2009, 2014; Van Ameringen et al., 2010; Leppink
et al., 2017). Data were de-identified according to the
Safe Harbor method for deidentification before data
sharing [section 164.514(b)] (U.S. Department of Health
& Human Services, 2012). After all the procedures were
explained, all participants provided written informed
consent.
All participants in the trials completed a full psychiatric
assessment using the Structured Clinical Interview for
DSM-IV (SCID-I) (First et al., 1995). Participants also
completed general demographic questionnaires, and self-
report and clinician-administered severity measures. In
addition, each participant underwent a semistructured
interview to examine psychiatric disorders in first-degree
relatives (except for the sertraline study). No relatives
were interviewed directly.
Assessments
The Massachusetts General Hospital Hair Pulling Scale
(MGH-HPS) (Keuthen et al., 1995) was used to assess the
severity of TTM symptoms. The MGH-HPS is a valid
and reliable, seven-item, self-report scale that rates urges
to pull hair, actual amount of pulling, perceived control
over behavior, and distress associated with hair pulling
over the preceding 7 days. Analysis of the MGH-HPS has
shown two separate factors with acceptable reliability for
both: ‘severity’ and ‘resistance and control’ (Keuthen
et al., 2007).
Psychosocial functioning was assessed using the Sheehan
Disability Scale (Sheehan, 1983). The Sheehan
Disability Scale is a valid and reliable, three-item, self-
report scale that assesses psychosocial functioning in
work, social or leisure activities, and home/family life.
Scores on the scale range from 0 to 30, with higher scores
indicating better perceived psychosocial functioning.
Depression and anxiety symptoms over the past month
were assessed using a clinician-administered Hamilton
Depression Rating Scale (Hamilton, 1960) and Hamilton
Anxiety Rating Scale (Hamilton, 1959), respectively.
Scores on these two measures were not a basis for
inclusion/exclusion.
Data analysis
Baseline characteristics of the placebo participants pooled
from all of the studies were presented in terms of means
and SDs for continuous variables and frequencies and
percentages for categorical variables.
Patients were grouped as placebo responders (>35%
reduction in MGH-HPS total scores from the baseline to
the end-point) or nonresponders. The two groups were
compared on pertinent demographic and clinical mea-
sures using independent-sample t-tests or equivalent
nonparametric tests as indicated in the text. This being
an exploratory study, statistical significance was defined
as P less than 0.05 uncorrected, one tailed.
As a secondary analysis, we also pooled all data from the
same studies from active treatment responders and
compared these data with those of placebo responders.
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Results
Data from 104 participants with primary TTM [91
(87.5%) women, mean age 32.6 ± 11.0 years] who were
assigned placebo were included in the analysis. In the
pooled analysis, 31.4% of participants assigned to placebo
improved at least 35% on the MGH-HPS during placebo
treatment.
In terms of the individual studies, the sample sizes for
those receiving placebo, and N (%) of patients respond-
ing to placebo, were as follows: Inositol N= 19, seven
(36.8%) were placebo responders; N-acetylcysteine
N= 25, six (24.0%) were placebo responders; Naltrexone
N= 30, nine (30.0%) were placebo responders;
Olanzapine N= 12, three (25.0%) were placebo respon-
ders; Sertraline N= 18, seven (39.9%) were placebo
responders. The studies did not differ significantly on the
placebo response rate (Likelihood ratio= 1.619, d.f.= 4,
P= 0.805).
Clinical variables of responders and nonresponders are
presented in Table 1, where it can be seen that the
groups did not differ from each other in terms of demo-
graphic variables or clinical characteristics. Clinical vari-
ables of placebo responders are compared with reference
data for active treatment responders in Table 2. Active
treatment responders completed significantly more study
weeks than placebo responders and had a marginally
higher rate of OCD (although OCD was uncommon in
both groups).
Discussion
To our knowledge, this is the first study that has examined
clinical variables associated with the placebo response in
the pharmacological treatment of TTM. Given that the
pooled placebo response in these studies was 31%, and
that there is as of yet no Food and Drug Administration-
approved medication indicated for the treatment of TTM,
determining predictors of placebo response is crucial for
the timely and cost-effective development of pharmaco-
logical interventions. Knowledge of variables associated
with placebo response might also be useful for sample
enrichment in clinical trials. In addition, a placebo
response rate of 31% suggests that larger numbers will be
needed in future placebo-controlled efficacy studies of
TTM than have been previously considered necessary.
Some research suggests that the placebo effect in clinical
drug trials generally may influence as many as 49% of
treated patients, that the effect may be related to
symptom severity, and that its duration may vary from
minutes to years (Breidert and Hofbauer, 2009).
Interestingly, the placebo response rate in our sample is
much higher than found previously in OCD treatment
trials, a disorder with possible biological links to TTM
(< 20%; Greist et al., 1995; Stein et al., 1995; Pigott and
Seay, 1999; Ackerman and Greenland, 2002; Stein et al.,
2006). Whether this difference is reflective of methodo-
logical issues or more substantial biological differences
between TTM and OCD, however, remains unclear.
This study found no differences between those who did
and did not respond to placebo.
Contrary to our expectations, baseline symptom severity
did not differ between placebo responders and non-
responders. The differences between our results and
studies of other mental health conditions such as major
depressive disorder in which baseline symptom severity
was a meaningful predictor of placebo response (Stein
et al., 2006; Nierenberg et al., 2015) could reflect the
Table 1 Clinical variables of participants with trichotillomania who did and did not respond to placebo
Variables
Those who responded to
placebo (n=32)
Those who did not respond to
placebo (n=72) Statistical test P value
Age (years) 30.4 (10.9) 33.5 (11.0) t=1.314, d.f.=1,102 0.192
Sex (female) 28 (87.5) 63 (87.5) LR=0.772, d.f.=2a 0.680
Education level 3.6 (1.2) 3.6 (1.3) t=0.062, d.f.=1, 68 0.951
Race (Caucasian) 20 (98.0) 48 (98.0) LR=0.691, d.f.=1 0.406
Frequency of hair pulling (mean number of minutes per day
during the week before study entry)
66.6 (38.6) 87.7 (67.1) t=1.379, d.f.=1, 72 0.172
MGH-HPS total score at baseline 17.4 (3.4) 18.2 (4.6) t=0.881, d.f.=1, 102 0.380
Weeks of study completed 8.5 (3.6) 8.3 (3.9) t= ˗0.193, d.f.=1, 72 0.848
Previous treatment for trichotillomania (yes) 14 (63.6) 29 (56.9) LR=0.294, d.f.=1 0.588
First-degree relative with grooming disorder (yes) 3 (13.6) 6 (11.5) LR=0.063, d.f.=1 0.803
Sheehan Disability Scale 10.9 (6.7) 9.3 (6.3) t=0.928, d.f.=1, 102 0.357
HAM-A 4.2 (3.4) 4.7 (3.9) t=0.489, d.f.=1, 72 0.626
HAM-D 5.6 (5.9) 6.6 (6.9) t=0.633, d.f.=1, 102 0.509
Lifetime psychiatric history
Mood disorder 14 (63.6) 19 (36.5) LR=0.0, d.f.=1 0.989
Anxiety disorder 5 (22.7) 9 (17.3) LR=0.288, d.f.=1 0.591
Alcohol use disorder 1 (4.5) 3 (5.8) LR=0.047, d.f.=1 0.829
OCD 0 (0) 2 (3.8) LR=1.435, d.f.=1 0.231
ADHD 1 (4.5) 9 (17.3) LR=2.561, d.f.=1 0.145
All values are mean (SD) for continuous variables and n (%) for categorical variables.
ADHD, attention-deficit/hyperactivity disorder; HAM-A, Hamilton Anxiety Rating Scale; HAM-D, Hamilton Depression Rating Scale; LR, likelihood ratio test;
OCD, obsessive-compulsive disorder.
aOne individual in the nonplacebo responders group identified as intersex.
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particular characteristics of our patient population or of
the disorder itself. Surprisingly, in view of the contribu-
tion of placebo response toward clinical outcomes in
trials, relatively few studies have explored predictors of
placebo response, especially so in obsessive-compulsive
and related disorders. Our findings of a lack of predictive
variables are in broad agreement with several previous
papers in OCD, which reported in statistically significant
predictors (DeVeaugh-Geiss et al., 1990; Mataix-Cols
et al., 1999).
Our comparison of baseline characteristics between pla-
cebo responders and active treatment responders (data
pooled from the same source studies) was similarly
negative, except for two findings. Active treatment
responders remained in the trials for a longer period of
time and had a marginally higher occurrence of OCD
than placebo responders. The former result probably
stems from greater treatment benefit that participants
may experience with at least some of the active treat-
ments reported in the literature, compared with placebo,
even if placebo participants respond somewhat to pla-
cebo. The latter result is likely a chance finding as the
actual numbers of patients with OCD were low in both
groups, and data were generally from randomized trials.
One possible explanation for the high placebo response
in TTM studies could be the phenotypic variation
encountered in the disorder. For example, some indivi-
duals pull only from their eyebrows or eyelashes. In these
cases, it is quite common to pull all of the hair and then
report no pulling for several weeks until the hair regrows.
This is quite distinct from individuals who pull from their
heads as that variation tends to be more chronic.
Of course, a complication is that many individuals pull
from several areas as well. Having said that, future studies
may aim to enroll only those who pull from their heads
and therefore have a chronic and predictable course so
that change in behavior could more reliably be attributed
to the intervention and not the lack of hair or need for
hair to regrow.
This study suggests that few (if any) typically collected
baseline clinical characteristics in TTM distinguish pla-
cebo responders from nonresponders, but there exist
several limitations to the studies included in the pooled
analysis. Some studies unrelated to TTM suggest that
expectancy (i.e. an individual’s beliefs about whether he
or she will improve because of the treatment) may play a
large role in a placebo response (Brown, 1994; Linden,
2017). Expectancy was not measured in the studies ana-
lyzed here. Although the MGH-HPS scoring has shown
strong validity and reliability in previous trials as reflect-
ing a response to medication, the ideal threshold for
response remains somewhat in doubt (Houghton et al.,
2015). We chose a 35% reduction as being clinically
meaningful, but some authors suggest that a 45% reduc-
tion may be more optimal for TTM (Houghton et al.,
2015). In response to this suggestion, we also examined
the current measures using a 45% definition in a post-hoc
analysis (Grant JE, Redden SA, Chamberlain SR,
unpublished data), with a similar lack of significant
results. Some clinical measures were available only for a
subset of individuals in the pooled dataset. This study did
not examine baseline cognition or brain function. Such
types of baseline measures would merit scrutiny in future
work. This may in the future be a useful means of dis-
tinguishing placebo responders from nonresponders
before treatment, especially given that the placebo
response can be linked to changes in brain functioning in
Table 2 Clinical variables of participants with trichotillomania who were placebo responders compared with active treatment responders
Variables
Those who responded
to placebo (n=32)
Those who responded to
active treatment (n=52) Statistical test P value
Age (years) 30.4 (10.9) 32.6 (11.1) t=0.865, d.f.=1, 82 0.390
Sex (female) 28 (87.5) 44 (84.6) LR=0.992, d.f.=2a 0.601
Education level 3.6 (1.2) 3.8 (1.0) t=0.638, d.f.=1, 55 0.527
Race (Caucasian) 20 (98.0) 33 (94.3) LR=1.851, d.f.=1 0.396
Frequency of hair pulling (mean number of minutes
per day during the week before study entry)
66.6 (38.6) t=1.379, d.f.=72 0.172
MGH-HPS total score at baseline 17.4 (3.4) 17.9 (4.1) t=0.619, d.f.=1, 82 0.538
Weeks of study completed 8.5 (3.6) 10.2 (2.2) t=2.073, d.f.=1, 56 0.047
Previous treatment for trichotillomania (yes) 14 (63.6) 20 (55.6) LR=0.370, d.f.=1 0.543
First-degree relative with grooming disorder (yes) 3 (13.6) 6 (16.7) LR=0.097, d.f.=1 0.755
Sheehan Disability Scale 10.9 (6.7) 11.4 (7.0) t=1.145, d.f.=1, 56 0.258
HAM-A 4.2 (3.4) 4.2 (0.5) t=0.044, d.f.=1, 56 0.965
HAM-D 5.6 (5.9) 6.0 (8.1) t=1.323, d.f.=1, 80 0.190
Lifetime psychiatric history
Mood disorder 14 (63.6) 16 (44.4) LR=0.370, d.f.=1 0.543
Anxiety disorder 5 (22.7) 9 (25.0) LR=0.039, d.f.=1 0.844
Alcohol use disorder 1 (4.5) 0 (0.0) LR=1.968, d.f.=1 0.161
OCD 0 (0) 4 (11.1) LR=3.995, d.f.=1 0.046
ADHD 1 (4.5) 5 (13.9) LR=1.433, d.f.=1 0.231
All values are mean (SD) for continuous variables and n (%) for categorical variables. Bold values are statistically significant (P< .05).
ADHD, attention-deficit/hyperactivity disorder; HAM-A, Hamilton Anxiety Rating Scale; HAM-D, Hamilton Depression Rating Scale; LR, likelihood ratio test;
OCD, obsessive-compulsive disorder.
aOne individual in the nonplacebo responders group identified as intersex.
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other contexts (Leuchter et al., 2002). The studies inclu-
ded in the present paper had some restrictions on
comorbidity in the protocols, which might explain the low
rates of comorbid OCD or alcohol use disorder. If the
studies had broader inclusion criteria allowing for comor-
bidity, it is possible that certain co-occurring disorders
may have contributed toward the placebo response. The
duration of treatment by week is reported and thus it
would be important to analyze the placebo for each week
of the studies. Given the collective data, this was not
possible across all studies and should be noted as a lim-
itation. Finally, although this study represents the largest
sample of participants in treatment trials for TTM, the
sample size is still relatively small and thus had only
modest power to detect moderate effect size. The current
sample size, however, had adequate power (power=
∼ 0.80) to detect a group difference on a given measure of
interest with medium (Cohen’s D≥ 0.6) effect size and it
had very high power (power=∼ 0.96) to detect a group
difference with large effect size (Cohen’s D= 0.8).
Placebo-controlled studies are the gold standard for the
examination of pharmacological interventions. Individuals
with TTM who respond to placebo appear no different
clinically from those who do not respond to placebo on
the basis of the types of measure typically collected in
existing clinical trials. Given the fairly high estimated
prevalence of TTM (Christenson et al., 1991; Odlaug and
Grant, 2010) and the associated reduced quality of life in
those who struggle with this disorder (Odlaug et al., 2010;
Tung et al., 2014; Houghton et al., 2016), further
exploration of placebo response will be crucial for devel-
oping better pharmacological interventions. Of course, it
is not possible to discuss meaningfully treatment resis-
tance in TTM as there is no licensed treatment and only a
limited evidence base of efficacy for any treatment.
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